PMID: 7581361Aug 1, 1995Paper

Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice

Human Molecular Genetics
S R PhelpsJ S Chamberlain

Abstract

Duchenne and Becker muscular dystrophy are caused by defects in the dystrophin gene, and are candidates for treatment by gene therapy. We have shown previously that overexpression of a full-length dystrophin cDNA prevents the development of dystrophic symptoms in mdx mice. We show here that this functional correction can be achieved by expressing the full-length muscle isoform at a lower level than is present in control animals. Gene therapy for DMD may necessitate the use of truncated dystrophin mini-genes to accommodate the limited cloning capacity of current-generation viral delivery vectors. We have constructed both murine and human mini-genes deleted for exons 17-48, and have demonstrated that expression of either mini-gene can almost completely prevent the development of dystrophic symptoms in transgenic mdx mice. These results suggest that viral-mediated expression of moderate levels of a truncated dystrophin could be an effective treatment for DMD.

Citations

May 8, 2000·Muscle & Nerve·M H DisatnikT A Rando
Nov 20, 2002·The Journal of Gene Medicine·Christopher J MannStephen D Wilton
Feb 14, 2006·Current Neurology and Neuroscience Reports·Jerry R Mendell, K Reed Clark
May 21, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Sarah L DeVos, Timothy M Miller
Aug 30, 2005·The International Journal of Biochemistry & Cell Biology·Geoffrey Goldspink
Jan 26, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mingju LiuDongsheng Duan
Jun 11, 2002·Biochemical and Biophysical Research Communications·Miki SakamotoShin'ichi Takeda
Sep 11, 2002·Neuromuscular Disorders : NMD·Dominic J Wells, Kim E Wells
Sep 11, 2002·Neuromuscular Disorders : NMD·Jeannine M ScottJeffrey S Chamberlain
Sep 11, 2002·Neuromuscular Disorders : NMD·G DicksonS A Fabb
Feb 3, 1998·Neuromuscular Disorders : NMD·K E Davies
Jul 10, 2003·Lancet Neurology·Robert KapsaEdward Byrne
Jun 27, 2009·Expert Reviews in Molecular Medicine·Lindsey A Muir, Jeffrey S Chamberlain
Jun 12, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Natee JearawiriyapaisarnRyszard Kole
Sep 4, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Helen FosterGeorge Dickson
Mar 13, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ryoko KawanoMakoto Uchino
Nov 6, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·En KimuraJeffrey S Chamberlain
Oct 7, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Paul S SharpDominic J Wells
Apr 7, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Christophe PichavantJacques P Tremblay
Jul 27, 2004·Nature Medicine·Paul GregorevicJeffrey S Chamberlain
Apr 19, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·DeWayne TownsendJoseph M Metzger
Apr 12, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zejing WangRainer Storb
May 12, 2010·Proceedings of the National Academy of Sciences of the United States of America·Davin M HendersonJames M Ervasti
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·N DeconinckJ M Gillis
Jul 1, 1996·The Journal of Cell Biology·J A RafaelJ S Chamberlain
Aug 1, 1996·The Journal of Experimental Medicine·D S ChaoD S Bredt
Sep 16, 2008·Human Gene Therapy·Juan LiXiang-Qin Liu
Sep 22, 2006·Human Molecular Genetics·Dongsheng Duan
Feb 16, 2010·Human Molecular Genetics·William LostalIsabelle Richard
Mar 26, 2011·Human Molecular Genetics·Aurélie GoyenvalleJeffrey Chamberlain
Mar 19, 2009·ILAR Journal·Zejing WangRainer Storb
Sep 12, 2009·Current Opinion in Neurology·Stanley F NelsonMelissa J Spencer
Aug 1, 2009·Development, Growth & Differentiation·Morris BeshayRalph A Schmid

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.